Sciences Ltd. Roivant Acquires 179,193 Shares of Myovant Sciences Ltd (NYSE:MYOV) Stock

Myovant Sciences Ltd (NYSE:MYOV) major shareholder Sciences Ltd. Roivant purchased 179,193 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was acquired at an average cost of $18.44 per share, with a total value of $3,304,318.92. Following the completion of the acquisition, the insider now directly owns 44,623,079 shares of the company’s stock, valued at $822,849,576.76. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Sciences Ltd. Roivant also recently made the following trade(s):

  • On Wednesday, December 4th, Sciences Ltd. Roivant purchased 75,000 shares of Myovant Sciences stock. The stock was acquired at an average cost of $17.06 per share, with a total value of $1,279,500.00.
  • On Monday, November 25th, Sciences Ltd. Roivant purchased 3,500,000 shares of Myovant Sciences stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $52,500,000.00.
  • On Wednesday, November 20th, Sciences Ltd. Roivant purchased 121,906 shares of Myovant Sciences stock. The stock was acquired at an average cost of $12.90 per share, with a total value of $1,572,587.40.

Shares of MYOV stock traded down $1.30 during trading hours on Wednesday, hitting $17.32. The stock had a trading volume of 3,799,900 shares, compared to its average volume of 777,728. The firm has a market capitalization of $1.67 billion, a PE ratio of -4.23 and a beta of 2.02. Myovant Sciences Ltd has a twelve month low of $4.14 and a twelve month high of $26.02. The stock’s 50 day moving average is $8.74 and its 200 day moving average is $8.20. The company has a debt-to-equity ratio of 5.88, a current ratio of 2.79 and a quick ratio of 2.79.

Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.07). As a group, equities analysts predict that Myovant Sciences Ltd will post -3.29 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of MYOV. Tower Research Capital LLC TRC lifted its holdings in shares of Myovant Sciences by 46.3% during the third quarter. Tower Research Capital LLC TRC now owns 9,741 shares of the company’s stock worth $51,000 after purchasing an additional 3,083 shares during the period. Barclays PLC lifted its holdings in shares of Myovant Sciences by 24.6% during the third quarter. Barclays PLC now owns 11,317 shares of the company’s stock worth $59,000 after purchasing an additional 2,234 shares during the period. Virginia Retirement Systems ET AL acquired a new stake in shares of Myovant Sciences during the third quarter worth $101,000. Northern Trust Corp acquired a new stake in shares of Myovant Sciences during the second quarter worth $105,000. Finally, Atria Investments LLC lifted its holdings in shares of Myovant Sciences by 87.9% during the second quarter. Atria Investments LLC now owns 22,915 shares of the company’s stock worth $162,000 after purchasing an additional 10,720 shares during the period. 38.81% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently weighed in on MYOV. JMP Securities reissued a “buy” rating and issued a $34.00 price objective on shares of Myovant Sciences in a report on Tuesday, November 19th. ValuEngine downgraded Myovant Sciences from a “buy” rating to a “hold” rating in a report on Tuesday. Svb Leerink began coverage on Myovant Sciences in a report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price objective for the company. Goldman Sachs Group reissued a “buy” rating and issued a $20.00 price objective (up from $18.00) on shares of Myovant Sciences in a report on Tuesday, November 19th. Finally, Leerink Swann began coverage on Myovant Sciences in a report on Monday, August 19th. They issued an “outperform” rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $23.46.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Story: What is the Shanghai Stock Exchange Composite Index?

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.